Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Margarita Salcedo‐Magguilli et al.|The Lancet Respiratory Medicine|2023Cited by 76
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trialBruno François, Pierre‐François Laterre, Simon Lambden et al.|BMJ Open|2021Cited by 20
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trialBruno François, Sébastien Gibot, Simon Lambden et al.|EClinicalMedicine|2023Cited by 18